3 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 Jan 24
Other Events
4:21pm
scans/year - 11,900 MRI systems in the US The mismatch between demographics, economics and drug availability is unsustainable AD – Finally Breakthroughs
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
12 Sep 23
Other Events
7:00am
performing 2M scans/year - 11,900 MRI systems in the US The mismatch between demographics, economics and drug availability is unsustainable AD
8-K
EX-99.2
CGTX
Cognition Therapeutics Inc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
(VMDS) - Exploratory – biomarkers – pending Study Design
Topline Data Overview Disposition and demographics Safety and tolerability Topline EEG … : - 31.3% ApoE e3/e3 - 37.5% ApoE e3/e4 - 31.3% ApoE e4/e4 Time since diagnosis: 1.14 years COG0202 Disposition and Demographics Disposition
- Prev
- 1
- Next